191 related articles for article (PubMed ID: 22620009)
1. [Hematopoietic malignancy (leukemia, malignant lymphoma, multiple myeloma)].
Nosaka K; Kawaguchi T
Nihon Rinsho; 2012 May; 70(5):835-9. PubMed ID: 22620009
[TBL] [Abstract][Full Text] [Related]
2. [Clinical values of biomarkers in hematopoietic malignancies].
Kawaguchi T; Nosaka K
Gan To Kagaku Ryoho; 2009 Jan; 36(1):26-31. PubMed ID: 19151562
[TBL] [Abstract][Full Text] [Related]
3. [Significance of tumor markers in the treatment of cancer: hematologic malignancy].
Sampi K
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3041-5. PubMed ID: 3674891
[TBL] [Abstract][Full Text] [Related]
4. [The minimal residual disease (MRD) in hematological malignancies].
Yokota S; Okamoto T
Gan To Kagaku Ryoho; 2001 Jun; 28(6):762-8. PubMed ID: 11432342
[TBL] [Abstract][Full Text] [Related]
5. [Optimising therapy in patients with haematological malignancies].
Dumontet C
Bull Cancer; 2008 Oct; 95(10):959-62. PubMed ID: 19004726
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms.
Ferrero S; Drandi D; Mantoan B; Ghione P; Omedè P; Ladetto M
Hematol Oncol; 2011 Dec; 29(4):167-76. PubMed ID: 22678691
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease monitoring: the new standard for treatment evaluation of haematological malignancies?
Hauwel M; Matthes T
Swiss Med Wkly; 2014 Jan; 144():w13907. PubMed ID: 24452390
[TBL] [Abstract][Full Text] [Related]
8. [Molecular diagnosis of leukemia and lymphoma].
Iida S; Ueda R
Rinsho Byori; 1994 Apr; 42(4):364-71. PubMed ID: 8176845
[TBL] [Abstract][Full Text] [Related]
9. The significance of minimal residual disease in stem cell grafts and the role of purging: is it better to purge in vivo or in vitro?
Melillo L; Cascavilla N; Lerma E; Corsetti MT; Carella AM
Acta Haematol; 2005; 114(4):206-13. PubMed ID: 16269860
[TBL] [Abstract][Full Text] [Related]
10. Molecular diagnosis of hematopoietic and lymphoid neoplasms.
Jevremovic D; Viswanatha DS
Hematol Oncol Clin North Am; 2009 Aug; 23(4):903-33. PubMed ID: 19577174
[TBL] [Abstract][Full Text] [Related]
11. Application of allele-specific quantitative PCR using genomic DNA to monitor minimal residual disease based on mutant gene levels following allogeneic hematopoietic stem cell transplantation in patients with hematological malignancies: comparison of mutant levels with autologous DNA percentage by short tandem repeat-PCR.
Taira C; Matsuda K; Saito S; Sakashita K; Sugano M; Okumura N; Honda T
Clin Chim Acta; 2012 Feb; 413(3-4):516-9. PubMed ID: 22138486
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic tumors and metastases involving bone.
Kim SH; Smith SE; Mulligan ME
Radiol Clin North Am; 2011 Nov; 49(6):1163-83, vi. PubMed ID: 22024293
[TBL] [Abstract][Full Text] [Related]
13. Recipient-derived cells after cord blood transplantation: dynamics elucidated by multicolor FACS, reflecting graft failure and relapse.
Watanabe N; Takahashi S; Ishige M; Ishii Y; Ooi J; Tomonari A; Tsukada N; Konuma T; Kato S; Sato A; Tojo A; Nakauchi H
Biol Blood Marrow Transplant; 2008 Jun; 14(6):693-701. PubMed ID: 18489995
[TBL] [Abstract][Full Text] [Related]
14. [DNA diagnosis in hematological malignancies].
Nara N
Rinsho Byori; 2001 Mar; Suppl 115():37-44. PubMed ID: 11391935
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy with interleukin-2 after hematopoietic cell transplantation for hematologic malignancy.
Margolin K; Forman SJ
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S33-8. PubMed ID: 10685656
[TBL] [Abstract][Full Text] [Related]
16. Detection of minimal residual disease by polymerase chain reaction in B cell malignancies.
Moos M; Schulz R; Cremer F; Sucker C; Schmohl D; Döhner H; Goldschmidt H; Haas R; Hunstein W
Stem Cells; 1995 Dec; 13 Suppl 3():42-51. PubMed ID: 8747988
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies.
Muñoz L; Nomdedéu JF; López O; Carnicer MJ; Bellido M; Aventín A; Brunet S; Sierra J
Haematologica; 2001 Dec; 86(12):1261-9. PubMed ID: 11726317
[TBL] [Abstract][Full Text] [Related]
18. The evolving use of serum free light chain assays in haematology.
Pratt G
Br J Haematol; 2008 May; 141(4):413-22. PubMed ID: 18318757
[TBL] [Abstract][Full Text] [Related]
19. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies.
Laurenti L; Chiusolo P; Garzia MG; Zini G; Sorà F; Piccirillo N; Piccioni P; Zollino M; Leone G; Sica S
Haematologica; 2002 Jan; 87(1):59-66. PubMed ID: 11801466
[TBL] [Abstract][Full Text] [Related]
20. Malignant epithelial tumors and hematologic malignancy.
Marković-Glamocak M; Sucić M; Ries S; Gjadrov-Kuvezdić K; Labar B
Diagn Cytopathol; 2008 Oct; 36(10):710-4. PubMed ID: 18773444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
